As in PBMCs from AD patients, results showed that C16 significantly reduced the levels of intracellular and extracellular cytokines in PBMCs from healthy patients (about 99% for IL-1β and IL-6 and 94% for TNF-α) (Table 3). This evidence concerns the gene IL6 and Alzheimer disease.